New Therapeutics for Ulcerative Colitis

Annu Rev Med. 2021 Jan 27;72:199-213. doi: 10.1146/annurev-med-052919-120048.


Ulcerative colitis (UC) is a relapsing and remitting inflammatory disease of the colon with a variable course. Despite advances in treatment, only approximately 40% of patients achieve clinical remission at the end of a year, prompting the exploration of new treatment modalities. This review explores novel therapeutic approaches to UC, including promising drugs in various stages of development, efforts to maximize the efficacy of currently available treatment options, and non-medication-based modalities. Treatment approaches which show promise in impacting the future of UC management are highlighted.

Keywords: Crohn's disease; anti-adhesion therapy; anti-interleukin inhibitor; inflammatory bowel disease; janus kinase inhibitor; sphingosine receptor modulator; ulcerative colitis.

Publication types

  • Review

MeSH terms

  • Anti-Ulcer Agents / therapeutic use*
  • Colitis, Ulcerative / therapy*
  • Fecal Microbiota Transplantation / methods*
  • Humans
  • Hyperbaric Oxygenation / methods*
  • Immunologic Factors / therapeutic use*
  • Janus Kinase Inhibitors / therapeutic use*
  • Sphingosine 1 Phosphate Receptor Modulators / therapeutic use*


  • Anti-Ulcer Agents
  • Immunologic Factors
  • Janus Kinase Inhibitors
  • Sphingosine 1 Phosphate Receptor Modulators